Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon

Yusuke Kawai, Kenichi Hisamatsu, Hiromi Matsubara, Kazuhiro Dan, Satoshi Akagi, Katsumasa Miyaji, Mitsuru Munemasa, Yoshihisa Fujimoto, Kengo F. Kusano, Tohru Ohe

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.

Original languageEnglish
Pages (from-to)765-772
Number of pages8
JournalEuropean Heart Journal
Volume30
Issue number7
DOIs
Publication statusPublished - Apr 2009
Externally publishedYes

Fingerprint

No-Reflow Phenomenon
Nicorandil
Percutaneous Coronary Intervention
Intravenous Administration
Acute Coronary Syndrome
Control Groups
Vasodilation
Hemodynamics
Incidence

Keywords

  • Acute coronary syndrome
  • Nicorandil
  • Percutaneous coronary intervention
  • Slow coronary flow phenomenon

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. / Kawai, Yusuke; Hisamatsu, Kenichi; Matsubara, Hiromi; Dan, Kazuhiro; Akagi, Satoshi; Miyaji, Katsumasa; Munemasa, Mitsuru; Fujimoto, Yoshihisa; Kusano, Kengo F.; Ohe, Tohru.

In: European Heart Journal, Vol. 30, No. 7, 04.2009, p. 765-772.

Research output: Contribution to journalArticle

Kawai, Y, Hisamatsu, K, Matsubara, H, Dan, K, Akagi, S, Miyaji, K, Munemasa, M, Fujimoto, Y, Kusano, KF & Ohe, T 2009, 'Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon', European Heart Journal, vol. 30, no. 7, pp. 765-772. https://doi.org/10.1093/eurheartj/ehp077
Kawai, Yusuke ; Hisamatsu, Kenichi ; Matsubara, Hiromi ; Dan, Kazuhiro ; Akagi, Satoshi ; Miyaji, Katsumasa ; Munemasa, Mitsuru ; Fujimoto, Yoshihisa ; Kusano, Kengo F. ; Ohe, Tohru. / Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. In: European Heart Journal. 2009 ; Vol. 30, No. 7. pp. 765-772.
@article{1c81d059a01a4a1690ce3deafd33f8c0,
title = "Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon",
abstract = "Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.",
keywords = "Acute coronary syndrome, Nicorandil, Percutaneous coronary intervention, Slow coronary flow phenomenon",
author = "Yusuke Kawai and Kenichi Hisamatsu and Hiromi Matsubara and Kazuhiro Dan and Satoshi Akagi and Katsumasa Miyaji and Mitsuru Munemasa and Yoshihisa Fujimoto and Kusano, {Kengo F.} and Tohru Ohe",
year = "2009",
month = "4",
doi = "10.1093/eurheartj/ehp077",
language = "English",
volume = "30",
pages = "765--772",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon

AU - Kawai, Yusuke

AU - Hisamatsu, Kenichi

AU - Matsubara, Hiromi

AU - Dan, Kazuhiro

AU - Akagi, Satoshi

AU - Miyaji, Katsumasa

AU - Munemasa, Mitsuru

AU - Fujimoto, Yoshihisa

AU - Kusano, Kengo F.

AU - Ohe, Tohru

PY - 2009/4

Y1 - 2009/4

N2 - Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.

AB - Aims: To determine the effect of intravenous administration of nicorandil on slow coronary flow (SCF) phenomenon in patients undergoing percutaneous coronary intervention (PCI).Methods and resultsIn a preliminary study, 6 mg of nicorandil showed optimal efficacy for vasodilatation without causing significant haemodynamic instability. In the main study, a total of 408 patients were randomly assigned to receive intravenous administration of 6 mg of nicorandil immediately before PCI. The number of patients in the nicorandil group was 206 [acute coronary syndrome (ACS): 47, non-ACS: 159] and that in the control group was 202 (ACS: 61, non-ACS: 141). Nicorandil significantly decreased the incidence of post-procedural SCF phenomenon in both the ACS and non-ACS groups. The rate of target vessel revascularization (TVR) was significantly lower in the nicorandil group than in the control group in ACS patients.ConclusionOur simple procedure prevented SCF phenomenon not only in patients with ACS but also in patients with non-ACS without any adverse effect. Additionally our procedure reduced the rate of TVR in patients with ACS.

KW - Acute coronary syndrome

KW - Nicorandil

KW - Percutaneous coronary intervention

KW - Slow coronary flow phenomenon

UR - http://www.scopus.com/inward/record.url?scp=64849095094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849095094&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehp077

DO - 10.1093/eurheartj/ehp077

M3 - Article

C2 - 19276198

AN - SCOPUS:64849095094

VL - 30

SP - 765

EP - 772

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -